Valbonne, France, April 23, 2015 – TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, cost-effective, personalized T-cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today an amendment to the Ovasave® collaboration option, development and license agreement (Ovasave Agreement) with Trizell Holding SA (Trizell). In the agreement, TxCell will undertake a program to bring forward the preparation of Ovasave for phase III development and commercialization, notably in the areas of process and manufacturing development. To finance this program, Trizell will advance up to €1.1 million in funding that was initially due after the future exercise of Trizell’s option to Ovasave. In Trizell’s sole discretion it may finance a further €4.3 million. TxCell has appointed the Cell Therapy Catapult, a leading cell therapy organization, to undertake the process and manufacturing development of TxCell’s ASTrIA product platform under TxCell’s leadership. Ovasave, TxCell’s lead product, is currently in a phase IIb clinical trial for refractory Crohn’s disease (CATS29 study – see release of Dec 4, 2014). Top line results of this study are expected at the end of 2016 / early 2017.